Abstract
Patients with glycogen storage disease type 1b (GSD-1b) have neutropenia and neutrophil dysfunction that predispose to frequent infections and inflammatory bowel disease (IBD), for which granulocyte colonystimulating factor (GCSF) is given. To investigate the use and the value of GCSF treatment in GSD-1b, a retrospective registry of GSD-1 patients born between 1960 and 1995 in 12 European countries was established. Included were 57 GSD-1b patients. Unglycosylated GCSF was given to 18 patients, median age of starting therapy was 8 years, longest duration of therapy 7 years. Dose varied between 2–10 μg/kg, with a frequency from daily to twice per week. Neutropenia (defined as an absolute neutrophil count <0.5×109/1) was found in 49 patients. In untreated patients, a significant decrease of haemoglobin, platelet counts and leucocyte counts with increasing age (P<0.032,P<0.04 andP<0.001 respectively) was noted, whereas neutrophil counts remained low but stable with increasing age. In nine patients who were treated longer than 1 year, median neutrophil counts increased significantly and simultaneously median leucocyte counts and platelet counts decreased significantly. In all patients treated, the number and severity of infections decreased and the severity of IBD improved subjectively. The most serious complication of GCSF treatment was marked splenomegaly (four patients).Conclusion: in this retrospective study a significant haematological effect was documented and a subjective improvement of infections and inflammatory bowel disease. In view of the uncertainty, prospective controlled trials seem warranted to clarify the indication for the use of granulocyte colony-stimulating factor in this disease.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Abbreviations
- ESGSD :
-
European study on glycogen storage disease
- GCSF :
-
granulocyte colony stimulating factor
- GSD :
-
glycogen storage disease
- IBD :
-
inflammatory bowel disease
References
Altman DG (1991) Quantifying variability. In: Altman DG (ed) Practical statistics for medical research, 1st edn. Chapman and Hall, London, pp 33
Ardizzone S, Bollani S, Bettica P, Bevilacqua M, Molteni P, Bianchi PG (2000) Altered bone metabolism in inflammatory bowel disease: there is a difference between Crohn’s disease and ulcerative colitis. J Intern Med 247: 63–70
Arion WJ, Canfield WK, Callaway ES, Burger HJ, Hemmerle H, Schubert G, Herling AW, Oekonomopulos R (1998) Direct evidence for the involvement of two glucose 6-phosphate-binding sites in the glucose-6-phosphatase activity of intact liver microsomes—characterization of T1, the microsomal glucose 6-phosphate transport protein by a direct binding assay. J Biol Chem 273: 6223–6227
Burchell A (1990) Molecular pathology of glocose-6-phosphatase. FASEB J 4: 2978–2988
Calderwood S, Kilpatrick L, Douglas SD, Freedman M, Smith-Whitley K, Rolland M, Kurtzberg J (2001) Recombinant human granulocyte colony-stimulating factor therapy for patients with neutropenia and/or neutrophil dysfunction secondary to glycogen storage disease type 1b. Blood 97: 376–382
Carapeti M, Soede-Bobok A, Hochhaus A, Sill H, Touw IP, Goldman JM, Cross NCP (1997) Rarity of dominant-negative mutations of the GCSF receptor in patients with blast crisis of chronic myeloid leukemia or de novo acute leukemia. Leukemia 11: 1005–1008
Cowan FJ, Warner JT, Dunstan FDJ, Evans WD, Gregory JW, Jenkins HR (1997) Inflammatory bowel disease and predisposition to osteopenia. Arch Dis Child 76: 325–329
Dong F, Dale DC, Bonilla MA, Freedman M, Fasth A, Neijens HJ, Palmblad J, Briars GL, Carlsson G, Veerman AJP, Welte K, Löwenberg B, Touw IP (1997) Mutations in the granulocyte colony-stimulating factor receptor gene in patients with severe congenital neutropenia. Leukemia 11: 120–125
Fata F, Myers P, Addeo J, Grinberg M, Nawabi I, Cappell MS (1997) Cyclic neutropenia in Crohn's ileocolitis: efficacy of granulocyte colony-stimulating factor. J Clin Gastroenterol 24: 253–256
Fernandes J, Saudubray J-M, van den Berghe G (2000) Glycogen storage diseases. In: Fernandes J, Chen Y-T (eds) Inborn metabolic diseases, 3rd edn. Springer, Berlin Heidelberg New York, pp. 85–93
Fewtrell MS, Kinsey SE, Williams DM, Bishop NJ (1997) Bone mineralization and turnover in children with congenital neutropenia, and its relationship to treatment with recombinant human granulocyte-colony stimulating factor. Br J Haematol 97: 734–736
Frampton JE, Lee CR, Faulds D (1994) Filgrastim: a review of its pharmacological properties and therapeutic efficacy in neutropenia. Drugs 48: 731–760
Frampton JE, Yarker YE, Goa KL (1995) Lenograstim: a review of its pharmacological properties and therapeutic efficacy in neutropenia and related clinical settings. Drugs 49: 767–793
Hommes DW, Meenan J, Dijkhuizen S, Ten Kate FJ, Tytgat GN, Van Deventer SJ (1996) Efficacy of recombinant granulocyte colony-stimulating factor (rhG-CSF) in experimental colitis. Clin Exp Immunol 106: 529–533
Höglund M, Håkansson L, Venge P (1997) Effects of in vivo administration of G-CSF on neutrophil functions in healthy volunteers. Eur J Haematol 58: 195–202
Ishiguro A, Nakahata T, Amano Y, Yasaui K, Koike K, Komiyama A (1993) Improvement of neutropenia and neutrophil dysfunction by granulocyte colony-stimulating factor in a patient with glycogen storage disease type 1b. J Pediatr 152: 18–20
Lee PJ, Patel JS, Fewtrell M, Leonard JV, Bishop NJ (1995) Bone mineralisation in type 1 glycogen storage disease. Eur J Pediatr 154: 483–487
Lin B, Hiraiwa H, Pan CJ, Nordlie RC, Chou JY (1999) Type-1c glycogen storage disease is not caused by mutations in the glucose-6-phosphate transporter gene. Hum Genet 105: 515–517
Marcolongo R, Zambello R, Trentin L, Cassatella M, Gasparotto G, Agostini C (1995) Childhood onset cyclic neutropenia: G-CSF therapy restores neutrophil count but does not influence superoxide anion and cytokine release by neutrophils. Br J Haematol 89: 277–281
Narisawa K, Otomo H, Igarashi Y, Arai N, Otake M, Tada K, Kuzuya T (1983) Glycogen storage disease type 1b: microsomal glucose-6-phosphatase system in two patients with different clinical findings. Pediatrics 17: 545–549
Schroten H, Roesler J, Breidenbach T, Wendel U, Elsner J, Schweitzer S, Zeidler C, Burdach S, Lohmann-Matthes M, Wahn V, Welte K (1991) Granulocyte and granulocyte-macrophage colony-stimulating factors for treatment of neutropenia in glycogen storage disease type 1b. J. Pediatr 119: 748–754
Shanahan F, Bernstein CN (1993) Odd forms of inflammatory bowel disease: what can they tell us? Gastroenterology 104: 327–329.
Smit GPA (1993) The long-term outcome of patients with glycogen storage disease type 1a. Eur J Pediatr 152[suppl 1]: S52-S55
Spiekermann K, Roesler J (1995) G-CSF and neutrophil chemotaxis. Br J Haematol 90: 232–233
Turilli I, Bowers D, Aronson I, Woods L, Jacobs P (1995) G-CSF and neutrophil chemotaxis. Br. J. Haematol. 90: 232–232
Vestergaard P, Krogh K, Rejnmark L, Laurberg S, Mosekilde L (2000) Fracture risk is increased in Crohn's disease, but not in ulcerative colitis. Gut 46: 176–181
Visser G, Rake JP, Fernandes J, Labrune P, Leonard JV, Moses S, Ullrich K, Smit GPA (2000) Neutropenia, neutrophil dysfunction and inflammatory bowel disease in glycogen storage disease type 1b. J Pediatr 137: 187–191
Wallace JL, McKnight W, Asfaha S, Liu DY (1998) Reduction of acute and reactivated colitis in rats by an inhibitor of neutrophil activation. Am J Physiol 274: G802-G808
Author information
Authors and Affiliations
Corresponding author
Additional information
Published online: 17 July 2002
Rights and permissions
About this article
Cite this article
Visser, G., Rake, J.P., Labrune, P. et al. Granulocyte colony-stimulating factor in glycogen storage disease type 1b. Results of the European study on glycogen storage disease type 1. Eur J Pediatr 161, S83–S87 (2002). https://doi.org/10.1007/BF02680001
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF02680001